A Mulicenter, Multi-Arm, Randomized , Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziqone as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resection for Non-Muscle Invasiv
|Effective start/end date||12/16/16 → 12/15/17|
- Spectrum Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.